Exome analysis of treatment-related AML after APL suggests secondary evolution.
Exome analysis of treatment-related AML after APL suggests secondary evolution.
复制标题
APL 后治疗相关 AML 的外显子组分析表明二次进化。
DOI：
10.1111/bjh.15681
复制
发表时间：
2019
影响因子：
6.5
通讯作者：
中科院分区：
文献类型：
--
作者：
Wang,Tianjiao;Jacoby,MeaganA;Duncavage,EricJ;Miller,ChristopherA;Heath,Sharon;Rahme,Ramy;Fenaux,Pierre;Ades,Lionel;Renneville,Aline;Cassinat,Bruno;Takeshita,Akihiro;Asou,Norio;Miyazaki,Yasushi;Kiyoi,Hitoshi;Ravandi,Farhad;
治疗相关急性髓性白血病（tAML）和治疗相关骨髓增生异常综合征（tMDS）与多种类型的化疗和放疗相关（Wong et al，2015）。在使用全反式维甲酸（ATRA）/伊达比星/阿糖胞苷联合治疗急性早幼粒细胞白血病（APL）后，观察到了tAML和tMDS（Park et al，2014; Zompi & Viguie，2002; Ojeda-Uribe et al，2012; Park et al，2008; de The，2018）。目前还不清楚是否会出现tAML后，暴露于ATRA和三氧化二砷（ATO），这应该不会导致DNA损伤或克隆选择的细胞。
Treatment-related acute myeloid leukaemia (tAML) and treatment-related myelodysplastic syndrome (tMDS) have been associated with many types of chemotherapy and radiation (Wong et al, 2015). Both tAML and tMDS have been observed after treatment of acute promyelocytic leukaemia (APL) with combination all-trans retinoic acid (ATRA)/idarubicin/cytarabine (Park et al, 2014; Zompi & Viguie, 2002; Ojeda-Uribe et al, 2012; Park et al, 2008; de The, 2018). It is unknown whether tAML will emerge following exposure to ATRA and arsenic trioxide (ATO), which should not cause DNA damage or the clonal selection of